Nosocomial, or healthcare treatment-acquired infections (broadly labeled as 'hospital-acquired infections") are a growing problem. So why haven't they been a great business for pharmaceutical companies? Why are declines expected in sales this year?
Hospital Acquired Infections are a serious concern of healthcare and they should be a major concern of pharmaceutical drug development. However only a fraction of new drugs that have been approved are treating this scourge. At the same time, a number of key brands are declining in sales. This White Paper looks into the situation in 2009, what might happen in next few years, and the one exception to the trend that might point in a new direction for HAI treatments.
Download Free White Paper on HAI Treatments
